Daily Endocrinology Research Analysis
Three impactful endocrinology-related studies stood out today: a large translational cohort-plus-animal study shows GLP-1 receptor agonists reduce alcohol consumption whereas DPP-4 inhibitors do not; a UK Biobank cohort identifies distinct midlife cardiometabolic profiles—especially a high liver enzyme pattern—linked to early- and late-onset dementia; and a national Chinese cohort demonstrates that the atherogenic index of plasma (AIP) and hsCRP jointly predict incident diabetes with measurable
Summary
Three impactful endocrinology-related studies stood out today: a large translational cohort-plus-animal study shows GLP-1 receptor agonists reduce alcohol consumption whereas DPP-4 inhibitors do not; a UK Biobank cohort identifies distinct midlife cardiometabolic profiles—especially a high liver enzyme pattern—linked to early- and late-onset dementia; and a national Chinese cohort demonstrates that the atherogenic index of plasma (AIP) and hsCRP jointly predict incident diabetes with measurable mediation.
Research Themes
- Metabolic hormone therapeutics repurposed for neuropsychiatric disease
- Cardiometabolic profiling and dementia risk stratification
- Inflammation–lipid interactions as predictors of incident diabetes
Selected Articles
1. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake.
Using a large VA cohort with propensity score matching and reverse translational rodent experiments, GLP-1 receptor agonists were associated with greater reductions in AUDIT-C drinking scores than both unexposed comparators and DPP-4 inhibitor recipients. In mice and alcohol-dependent rats, DPP-4 inhibitors did not reduce alcohol intake despite lowering glucose, confirming specificity. Findings support GLP-1RA repurposing for alcohol use disorder.
Impact: This study provides convergent human and animal evidence that GLP-1RAs reduce alcohol intake, addressing a major public health burden and informing rapid translational trials. It also clarifies that DPP-4 inhibition does not confer similar benefits.
Clinical Implications: Consider GLP-1RA therapy in patients with AUD (especially with comorbid T2DM/obesity) while awaiting RCTs; do not expect DPP-4 inhibitors to reduce alcohol consumption. Screening for AUD in patients started on GLP-1RAs may identify additional benefit.
Key Findings
- GLP-1RA recipients had greater AUDIT-C score reductions than unexposed (DiD 0.09; 95% CI 0.03–0.14; P=0.0025) and DPP-4I recipients (DiD 0.11; 95% CI 0.05–0.17; P=0.0002).
- Effects were larger among individuals with baseline AUD and hazardous drinking (e.g., DiD up to 1.38 vs unexposed; P<0.0001).
- DPP-4 inhibitors showed no reduction in alcohol intake in humans and did not reduce drinking in mice or alcohol-dependent rats, despite lowering blood glucose.
- Reverse translational rodent studies confirmed target engagement for DPP-4Is (glucose lowering) but no effect on alcohol intake, underscoring pathway specificity.
Methodological Strengths
- Large nationwide EHR cohort (2008–2023) with propensity score matching and difference-in-difference estimation.
- Convergent reverse translational validation in two rodent models (binge drinking in mice; operant self-administration in alcohol-dependent rats).
Limitations
- Observational human data with potential residual confounding and reliance on self-reported AUDIT-C.
- Generalizability may be limited by the VA population; mechanisms within the GLP-1RA class and dose-response require RCTs.
Future Directions: Conduct randomized controlled trials testing specific GLP-1RAs for AUD, define mechanisms (central vs peripheral), and identify patient subgroups most likely to benefit.
BACKGROUNDDespite growing preclinical evidence that glucagon-like peptide1 receptor agonists (GLP-1RAs) could be repurposed to treat alcohol use disorder (AUD), clinical evidence is scarce. Additionally, the potential impact of dipeptidyl peptidase-4 inhibitors (DPP-4Is) on alcohol intake is largely unknown.METHODSWe conducted a large cohort study using 2008-2023 electronic health records data from the U.S. Department of Veterans Affairs. Changes in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) scores were compared between propensity-score-matched GLP-1RA recipients, DPP-4I recipients, and unexposed comparators. We further tested the effects of 2 DPP-4Is, linagliptin and omarigliptin, on binge-like alcohol drinking in mice and operant oral alcohol self administration in alcohol-dependent rats, models previously used to show a significant effect of the GLP-1RA semaglutide in reducing alcohol intake.RESULTSGLP-1RA recipients reported a greater reduction in AUDIT-C scores than unexposed individuals (difference-in-difference [DiD]: 0.09 [95% CI: 0.03, 0.14], P = 0.0025) and DPP-4I recipients (DiD: 0.11 [95% CI: 0.05,0.17], P = 0.0002). Reductions in drinking were more pronounced among individuals with baseline AUD (GLP-1RA versus unexposed: 0.51 [95% CI: 0.29,0.72], P < 0.0001; GLP-1RA versus DPP-4I: 0.65 [95% CI: 0.43,0.88], P < 0.0001) and baseline hazardous drinking (GLP-1RA versus unexposed: 1.38 [95% CI: 1.07,1.69], P < 0.0001; GLP-1RA versus DPP-4I: 1.00 [95% CI: 0.68,1.33], P < 0.0001). There were no differences between DPP-4I recipients and unexposed individuals. The latter results were confirmed via a reverse translational approach. Specifically, neither linagliptin nor omarigliptin reduced alcohol drinking in mice or rats. The rodent experiments also confirmed target engagemhent, as both DPP-4Is reduced blood glucose levels.CONCLUSIONConvergent findings across humans, mice, and rats indicated that GLP-1RAs, but not DPP-4Is, reduce alcohol consumption and may be efficacious in treating AUD.FUNDINGThis work was supported by the National Institutes of Health Intramural Research Program (ZIA DA000635, ZIA DA000644, ZIA DA000602), National Institute on Alcohol Abuse and Alcoholism extramural funding (R01 AA030041, P01 AA029545, U01 AA026224, U24 AA020794, U01 AA020790, U10 AA013566), the U.S. Department of Veterans Affairs (I01BX004820), and an Alkermes Pathways Research Award.
2. Data-driven discovery of midlife cardiometabolic profile associated with incident early-onset and late-onset dementia.
In 289,494 UK Biobank participants followed for a median 14.1 years, five cardiometabolic clusters were identified. A high liver enzyme pattern conferred the largest risk for early-onset dementia (HR 2.58) and also increased late-onset dementia risk, while an inflammation pattern increased late-onset dementia risk (HR 1.39). Associations were independent of APOE ε4 status.
Impact: Identifying distinct midlife cardiometabolic patterns that predict early- and late-onset dementia provides actionable targets for prevention beyond genetic risk, linking liver health and systemic inflammation to neurodegeneration.
Clinical Implications: Routine assessment of liver enzymes and systemic inflammation profiles in midlife could refine dementia risk stratification and motivate early interventions (e.g., metabolic/liver health optimization, anti-inflammatory strategies), irrespective of APOE ε4 genotype.
Key Findings
- Five data-driven cardiometabolic clusters were identified from 12 markers; the high liver enzymes pattern (cluster 3) showed the strongest association with early-onset dementia (HR 2.58; 95% CI 1.61–4.14).
- Cluster 3 also increased late-onset dementia risk (HR 1.36; 95% CI 1.09–1.71); an inflammation pattern (cluster 4) increased late-onset dementia risk (HR 1.39; 95% CI 1.13–1.72).
- No significant interactions with APOE ε4 genotype were detected, suggesting risk operates independently of this genetic factor.
Methodological Strengths
- Very large, prospective cohort with long follow-up (median 14.1 years) and rigorous cluster analysis across 12 cardiometabolic markers.
- Separate analyses for early- vs late-onset dementia with hazard modeling and assessment of APOE ε4 interactions.
Limitations
- Observational design cannot establish causality; residual and unmeasured confounding possible.
- Generalizability beyond the UK Biobank population may be limited; biomarker cutpoints and cluster reproducibility need external validation.
Future Directions: Validate clusters across diverse populations, test interventions targeting liver health and systemic inflammation in high-risk clusters, and integrate imaging/omics to elucidate mechanisms.
BACKGROUND: Cardiometabolic risk factors have been associated with the risk of late-onset dementia. However, evidence regarding early-onset dementia was inconsistent, and the impact of clustered cardiometabolic risk factors was unclear. We aimed to investigate the associations of cardiometabolic profiles with incident early-onset and late-onset dementia. METHODS: Among 289 494 UK Biobank participants, cluster analysis was built on 12 common cardiometabolic markers. Analyses were performed on those aged <65 years at baseline (n = 249 870) for early-onset dementia and those ≥65 at the end of follow-up (n = 191 213) for late-onset dementia. RESULTS: During a median follow-up of 14.1 years, 279 early-onset dementia cases and 3167 late-onset dementia cases were documented. Among the five clusters of cardiometabolic profiles identified (cluster 1 [obesity-dyslipidemia pattern], cluster 2 [high blood pressure pattern], cluster 3 [high liver enzymes pattern], cluster 4 [inflammation pattern] and cluster 5 [relatively healthy pattern]), cluster 3 was significantly associated with higher risks of both early-onset and late-onset dementia; however, the risk estimate for early-onset dementia (hazard ratio 2.58, 95% CI 1.61-4.14) was larger than that for late-onset dementia (1.36, 1.09-1.71). Cluster 4 was associated with a higher risk of late-onset dementia (hazard ratio 1.39, 95% CI 1.13-1.72). No significant interactions were observed between cardiometabolic clusters and apolipoprotein E ε4 genotype. CONCLUSIONS: Cardiometabolic patterns characterised by relatively high liver enzyme levels or systemic inflammation were associated with increased risks of early-onset and late-onset dementia. Identification of high-risk subgroups according to distinct cardiometabolic patterns might help develop more precise strategies for dementia prevention regardless of apolipoprotein E (APOE) ε4 status.
3. Atherogenic index of plasma, high sensitivity C-reactive protein and incident diabetes among middle-aged and elderly adults in China: a national cohort study.
In a national Chinese cohort (n=9,112; 5,048 followed), both high AIP and high hsCRP independently predicted incident diabetes over 4 years, with a stronger joint effect (aOR 2.76). Combining AIP and hsCRP modestly improved discrimination (AUC 0.628), and mediation analyses suggested bidirectional partial mediation between lipid atherogenicity and inflammation.
Impact: This study provides clinically actionable, low-cost biomarkers (AIP, hsCRP) for diabetes risk stratification in community settings and clarifies mechanistic interplay via mediation.
Clinical Implications: Incorporating AIP and hsCRP into routine assessments can refine diabetes risk stratification and guide early lifestyle or pharmacologic interventions targeting dyslipidemia and inflammation.
Key Findings
- Over 4 years, incident diabetes occurred in 9.7% (489/5,048); highest AIP quartile associated with diabetes (aOR 2.53; 95% CI 1.90–3.38).
- Highest hsCRP quartile also associated with diabetes (aOR 2.38; 95% CI 1.79–3.16); joint high AIP+hsCRP conferred aOR 2.76 (2.13–3.57).
- Combining AIP and hsCRP yielded better predictive performance (AUC 0.628) than either alone; mediation showed AIP mediated 25.4% of hsCRP→diabetes and hsCRP mediated 5.7% of AIP→diabetes.
Methodological Strengths
- Nationally representative cohort with multivariable adjustment, LME modeling, and ROC analysis.
- Formal mediation analysis to dissect interplay between lipid atherogenicity and inflammation.
Limitations
- Moderate discrimination (AUC 0.628) indicates room for improved models; potential residual confounding remains.
- Follow-up limited to 4 years; diabetes ascertainment may miss undiagnosed cases between waves.
Future Directions: Integrate AIP and hsCRP with genetic and metabolomic markers to enhance prediction and test targeted interventions reducing both atherogenic lipids and inflammation.
BACKGROUND: The atherogenic index of plasma (AIP) and systematic inflammation, as measured by high-sensitivity C-reactive protein (hsCRP), are predictors of diabetes, but their combined impacts on incident diabetes are poorly understood. Using a nationally representative cohort in China, we aimed to investigate the association of AIP and hsCRP with incident diabetes among middle-aged and elderly adults. METHODS: This cohort comprised 9,112 participants aged at least 45 years from 125 cities in the China Health and Retirement Longitudinal Study who were free of diabetes at baseline in 2011. Of these, 5,048 participants were followed up until 2015. The AIP was calculated as Log10[TG (mg/dL)/HDL-C(mg/dL)]. Multivariate logistic regression and linear mixed-effect (LME) models were performed to evaluate the associations of AIP, hsCRP, and incident diabetes as well as glycemic biomarkers. Receiver operating characteristic (ROC) curves were used to evaluate their diagnostic values. We conducted a mediation analysis to assess the direct and indirect associations between AIP and hsCRP with diabetes. RESULTS: 489 (9.7%) cases developed diabetes during four years. Higher levels of AIP and hsCRP were independently associated with diabetes. Compared to the lowest quartile of AIP or hsCRP, the highest quartile of AIP (adjusted odds ratio, aOR 2.53, 95% CI: 1.90-3.38) and hsCRP (aOR 2.38, 1.79-3.16) was significantly associated with incident diabetes. The joint effects showed that participants with higher levels of AIP and hsCRP had significantly higher aOR of 2.76 (2.13-3.57). The LME models showed AIP and hsCRP were related to an increased level of fasting blood glucose and glycated hemoglobin. The combination of AIP and hsCRP has better predictive efficacy (area under the curve, AUC: 0.628, 0.601-0.654) for incident diabetes than alone. Mediation analyses showed that high AIP significantly mediated 25.4% of the association between hsCRP and diabetes, and hsCRP simultaneously mediated 5.7% of the association between AIP and diabetes. CONCLUSIONS: This cohort suggests combined effects and mutual mediation between the AIP and hsCRP on incident diabetes in China. Our findings provide clinical implications for monitoring and managing AIP and hsCRP levels to mitigate the development of diabetes.